A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 and placebo in participants with HD.

Phase 2

PTC Therapeutics